Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07111338) titled 'Telitacicept for PGNMID: A Single-Arm Study' on Aug. 1.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Peking University First Hospital
Condition:
Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits
Intervention:
Drug: Telitacicept 160mg
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: July 12, 2025
Target Sample Size: 10
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07111338
Publis...